AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

ABBV•2026-09-30

AbbVie started a Phase 2 trial of obesity candidate ABBV-295 in adults with overweight or obesity in August 2026. Phase 1 results showed weight loss across dosing schedules and mainly mild side effects concentrated early in treatment.

1. Phase 2 trial starts

AbbVie started a Phase 2 trial of ABBV-295 in adults with overweight or obesity in August 2026. Phase 1 results presented at EASD 2026 showed meaningful weight loss across dosing schedules, with side effects mainly mild and concentrated early in treatment.

Sources

AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

Publicnow

AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

1. Phase 2 trial starts

Related News

Sagimet Biosciences suspends and terminates ATM prospectus supplement for Series A common stock effective Sept. 30

AbbVie says Phase 1 ABBV-295 study shows up to about 10% mean weight loss over three months

Goldman Sachs BDC files for offering of 5.100% notes due 2029, size not disclosed

Sources

AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295

H.C. Wainwright cuts Dyne Therapeutics target price to $32 from $50

Copper climbs on China factory data, heads for third-straight monthly gain